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The major events leading to both rheumatic fever (RF) and rheumatic heart disease (RHD)
are reviewed. Several genes are involved in the development of RF and RHD. The inflam-
matory process that results from S. pyogenes infection involves the activation of several
molecules such as VCAM and ICAM, which play a role in the migration of leukocytes to
the heart, particularly to the valves. Specific chemokines, such as CXCL3/MIP1α as well
as CCL1/I-309 and CXCL9/Mig, attract T cells to the myocardium and valves, respectively.
The autoimmune reactions are mediated by both the B- and T-cell responses that begin at
the periphery, followed by the migration of T cell clones to the heart and the infiltration of
heart lesions in RHD patients. These cells recognize streptococcal antigens and human-
tissue proteins. Molecular mimicry between streptococcal M protein and human proteins
has been proposed as the triggering factor leading to autoimmunity in RF and RHD. The
production of cytokines from peripheral and heart-infiltrating mononuclear cells suggests
that T helper 1 and Th17 cytokines are the mediators of RHD heart lesions. The low num-
bers of IL-4 producing cells in the valvular tissue might contribute to the maintenance and
progression of the valve lesions. The identification of a vaccine epitope opens a perspec-
tive of development of an effective and safe vaccine to prevent S. pyogenes infections,
consequently RF and RHD.
Keywords: S. pyogenes, genes, adhesion molecules, chemokines, Th1 and Th17 cytokines, T and B cells, valve
proteins, anti-S. pyogenes vaccine
INTRODUCTION
Rheumatic fever (RF) and its major sequelae rheumatic heart dis-
ease (RHD) are autoimmune diseases that arise following infection
of the throat by S. pyogenes in children and young individu-
als (3–19 years old) who present genetic components that confer
susceptibility to the disease.
The disease still remains a major cause of cardiovascular dis-
ability in school children and young individuals, and it represents
a high burden for public health in the developing world. The inci-
dence of this disease in the so-called “hotspots” ranges from 20
to 51 per 100,000 habitants, causing ∼500,000 deaths each year
(1). In Brazil, the number of beta hemolytic streptococcus throat
infections is ∼10 million cases/year, leading to 30,000 new cases
of RF, of which∼15,000 cases develop RHD (2).
The aim of this review is to explore the role of several genes
in the control of S. pyogenes infection and the associated autoim-
mune reactions, as well as to depict the molecular mechanisms
leading to these autoimmune reactions.
GENETIC BACKGROUND
As RF and RHD are post-infectious diseases that involve an inflam-
matory reaction in addition to T and B cells, several genes are
involved in the predisposition and manifestation of the disease.
Table 1 summarizes the genes involved in RF/RHD development
and their role.
GENES RELATED TO THE INNATE IMMUNE RESPONSE
The first line of host defense against a pathogen, S. pyogenes in
the cases of RF and RHD, involves several molecules that bind to
specific pathogen-associated molecular patterns (PAMPs) through
specific molecules in the host,defined as pattern recognition recep-
tors (PRRs). These PRRs can be soluble in human serum, or they
can be cell-associated, and they are described below.
Toll-like receptors (TLRs) are sensors of foreign microbial
products that initiate host defense responses in multicellular
organisms. The genotype 753Arg/Gln of TLR2 gene resulting from
the replacement of arginine with glutamine at codon 753 was
more frequently present in a Turkish ARF cohort compared with
controls (3).
Mannan-binding lectin (MBL) is a phase I inflammatory pro-
tein encoded by different variants of the promoter and exon 1
regions of the MBL2 gene. The A and O alleles code for high and
low production of MBL, respectively. Interestingly, RHD patients
with mitral stenosis (MS) displayed an association with the A allele,
while the majority of RHD patients with aortic regurgitation (AR)
presented the O allele. The amount of MBL in the sera of RF and
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Inadequate immune response against S. pyogenes
HLA class II genes
(DR and DQ, several
alleles)
Adaptive immune response
T cell antigen presentation and immune response
TNF-α, ILRA, TGF-β,
IL-10
Both innate immunity/adaptive immune response
Mediators of inflammatory reactions
RHD patients presented high and low serum levels of MBL, respec-
tively (4, 5). These results suggest that the MBL2 gene could play
a role in the development of valvular stenosis or regurgitation.
Ficolins trigger the innate immune response by either bind-
ing to collectin cellular receptors or initiating the complement
lectin pathway. There have been three ficolin genes identified in
humans with different functions, sequences, and specificity. Poly-
morphisms at −986, −602, and −4 within the promoter region
of ficolin 2 (FCN2) are associated with the serum levels of this
protein. In Brazilian chronic RHD patients, the haplotype G/G/A
(−986/−602/−4) was more frequent than in controls and corre-
lated with low levels of this protein, leading to a prolonged time
of infection or to repeated streptococcal infections (6).
GENES RELATED TO THE ADAPTIVE IMMUNE RESPONSE
The susceptibility of developing RF/RHD was first associated with
alleles of the HLA class II genes (DRB1, DQB, and DQA). Among
the DRB1 alleles, HLA-DR2, DR3, DR4, DR7 were the most fre-
quently associated with the disease, with HLA-DR7 being the most
consistently associated HLA allele found in Brazilian, Turkish,
Egyptian, and Latvian RF/RHD patients [reviewed in Ref. (7)].
The role of the HLA molecules encoded by these genes is to present
antigens to the T cell receptor (TCR), thus activating the adaptive
immune response.
GENES RELATED TO BOTH THE INNATE AND THE ADAPTIVE IMMUNE
RESPONSE
The TNF-α gene has an inflammatory role and is located on the
same chromosome as the HLA class II genes. The polymorphism
of a SNP at the promoter region of TNFA-308G/A was associated
with the susceptibility of patients from Mexico, Turkey, Brazil, and
Egypt to RHD (8–11).
IL-1α and IL-1β are cytokines that have been implicated in
the inflammatory reactions and are encoded by IL-1Ra gene. The
most common alleles are 1 and 2, which encode antagonists of
IL-1α and IL-1β. The absence or misrepresentation of both alle-
les results in a strong inflammatory response. Studies in Brazilian
RHD patients with severe carditis showed low frequencies of allele
1, suggesting the absence of inflammatory control (12). Some stud-
ies showed that alleles of the TGFβ1 gene were risk factors for
the development of valvular RHD lesions (13, 14) as this gene
codes for an inflammatory protein secreted by many cell types
including macrophages. Thus inflammatory stimuli that activate
macrophages enhance the release of active TGF-β.
HEART VALVE CHRONIC INFLAMMATION
The healing process of rheumatic carditis results in varying degrees
of fibrosis and valve damage. The Aschoff body is considered the
hallmark of the disease and consists of a granulomatous nod-
ule usually located in the connective tissue around small vessels.
This structure promotes the inflammatory process as the medi-
ator of rheumatic heart lesions. Several inflammatory cells, such
as neutrophils, macrophages, and T and B lymphocytes, infiltrate
both the myocardium and the valves. These cells enter through
the myocardium and the valves upon the upregulation of expres-
sion of the adhesion molecules. Cunningham’s group showed that
streptococcal heart-tissue cross-reactive antibodies increased the
amount of VCAM-1 on the valvular endothelial surface, lead-
ing to myocarditis and valvulitis (15, 16). Recently, we verified
that ICAM, another integrin, was also upregulated, in addition
to P-selectin and several chemokines and their receptors. Among
the chemokines, CCL3/MIP1α gene expression was up regulated
in the myocardium, while CCL1/I-309 and CXCL9/Mig were
highly expressed in the valvular tissue of RHD patients (17). An
in vitro assay demonstrated that valvular lesions infiltrating T cells
migrated mainly toward a CXCL9/Mig gradient, suggesting that
specific chemokines can mediated both the CD4+ and CD8+ T
cell recruitment to the site of inflammation in the heart (17).
Cytokines are important secondary signals following an infec-
tion because they trigger effective immune responses in most
individuals, and they most likely cause deleterious responses in
patients with autoimmune disease. Cytokines generally act locally.
In RHD, in both the myocardium and valvular tissue, a large
number of infiltrating mononuclear cells secreting IFNγ and
TNFα inflammatory cytokines were found. Interestingly, only
small numbers of IL-4 producing cells were found in the valves,
while several cells producing IL-10 were observed. These data
strongly indicated that the low numbers of IL-4 producing cells
may contribute to the progression of valve lesions in RHD
(18). Recently, we identified large numbers of IL-17 and IL-23-
producing cells in the valves; IL-17 and IL-23 are a Th17 subset
cytokines that are also frequently involved in the development of
autoimmune diseases (19). All of the events currently known to
be involved in inflammation and infiltration of the heart tissue by
T cells are summarized in Table 2.
AUTOIMMUNE REACTIVITY
The existence of similar or identical antigens in microbes (virus,
bacteria, and other pathogens) and their hosts enable the microbe
to evade the host immune response. The mechanism known as
“molecular mimicry,” by which self antigens are recognized after
an infection by cross reactivity, was introduced by Damian (20).
The presence of heart-reactive antibodies was described more
than 50 years ago in sera from animals immunized with strep-
tococcal cell wall products and in sera from acute RF and RHD
patients.
Using immunofluorescence techniques, Kaplan found
immunoglobulins and complement bound to the myocardium of
acute RF patients (21). Studies conducted by Zabriskie et al. gave
support to the hypothesis that RF has an autoimmune origin by
describing the presence of antibodies that were cross reactive with
streptococcal membrane antigens in acute RF sera (22).
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Many studies have focused on identifying the cross-reactive
streptococcal epitope recognized by antibodies in sera from both
animals and humans (23). Identification of the amino acid
sequences of the N-terminal portion of the M protein in the
1980s led to the discovery of cross-reactive epitopes. The mole-
cular mimicry between group A streptococcal proteins and several
human-tissue proteins leads to the autoimmune reactions in the
diverse phenotypes of the disease (24). Sydenham Chorea (SC),
one of the major manifestations of the disease affects the cen-
tral nervous system (CNS), in which lysoganglioside GM1 from
neuronal cells are the targets of cross-reactive antibodies against
N -acetyl-β-d-glucosamine, an antigen that is present in the cell
Table 2 | Molecules involved with heart-tissue cellular infiltration.
Adhesion molecules (VCAM, ICAM) P-selectin and integrins are
overexpressed in the heart-tissue and facilitates the cellular infiltration,
valve scarring
Specific chemokines such as CCL3/MIP1α gene expression up regulated
in the myocardium and CCL1/I-309 and CXCL9/Mig in the valves recruited
auto-reactive T cells
High numbers of TNF-α and IFN-γ, IL-17, and IL-23 secreting mononuclear
cells are mediators of myocardium and valvular inflammation and drive the
autoimmune response
Low numbers of mononuclear IL-4 secreting cells in the valves probably
lead to permanent and progressive valvular damage
Infiltrating T cells are predominantly CD4+ (∼80%)
Antigen-driven oligoclonal T cells are expanded in the myocardium and
valves and recognize streptococcal M peptides and heart-tissue proteins
by cross reactivity
The degeneracy of TCR and the epitope spreading mechanism allowed the
recognition of several streptococcal and human proteins with some
degree of homology (sequences or conformational or chemical properties)
wall of S. pyogenes (25). In RHD, the valves are severely damaged
by both humoral and cellular autoimmune reactions.
The role of the cellular arm of the immune response in RF only
began to be investigated 25 years after the description of heart-
reactive antibodies in the sera of RF patients. The first studies
focused on the reactivity of T cells from the peripheral blood of RF
and RHD patients against streptococcal M protein (26, 27). These
studies were followed by the description of increased numbers of
CD4+ cells in the tonsils and peripheral blood of RF patients when
compared with healthy subjects (28). The cytotoxic activity of
CD8+ T cells from normal peripheral blood toward immortalized
human heart cells was also described (29). It is now well established
that heart-tissue inflammation starts by pericarditis followed by
myocarditis and valvulitis, which cause serious damage to the heart
valves due to the infiltration of both auto-reactive antibodies and
T lymphocytes, leading to the development of valvular lesions and
consequently, RHD.
Notably, CD4+ cells are predominant in the rheumatic lesions
of the heart tissue. An analysis of the reactivity of both heart-tissue
infiltrating T cells and peripheral cells against both the N-terminal
region M protein-derived peptides and heart-tissue proteins noted
three immunodominant regions of the M5 protein (residues 1–
25, 81–103, and 163–177) that were cross reactive with both
myocardium and valve-derived proteins (26, 27). The recognition
of these regions was mainly in the context of the HLA-DR7 mol-
ecule, which is one of the most frequent HLA class II alleles asso-
ciated with the susceptibility of the disease, as mentioned above
(27). Among the heart-tissue proteins, cardiac myosin, the most
abundant protein in the myocardium, is one of the targets of strep-
tococcal cross-reactive antibodies and heart-tissue-infiltrating T
cells. The autoimmune reaction against several synthetic pep-
tides of the beta chain of the cardiac myosin light meromyosin
(LMM) region were described by Ellis et al. (30) and Fae et al. (31)
and are examples of autoreactivity against the myocardium tissue
FIGURE 1 |T cell reactivity against streptococcal M5 protein and
heart-tissue proteins. Valve-derived intralesional T cell clones from
three RHD patients who underwent surgery for valve correction were
established in vitro as previously described (26) and assayed for their
reactivity against mitral valve-derived proteins and synthetic peptides
of light meromyosin (LMM) and the M5 protein (26, 31). Black box:
positive reaction in proliferation assays with a stimulation index
(SI) >2.5.
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mediated by both antibodies and T cells. However, it is interesting
to note that the permanent rheumatic lesions occur in the valvular
tissue, most likely due to the migration of these auto-reactive T
cells from the myocardium to the valvular tissue. In the valves,
we found several T cell oligoclonal populations defined by the
analysis of the TCR (32, 33) that recognized M protein peptides
from the N-terminal region and human cardiac myosin beta-chain
peptides, as mentioned above, as well as valve tissue-derived pro-
teins (31), as summarized in Figure 1. Among the valve proteins,
we identified vimentin and disulfide isomerase ER-60 precursor
Table 3 | Properties of “StreptInCor” an anti-S. pyogenes candidate vaccine.
Characteristics Properties Reference
M protein C-terminal portion 55 Amino acids residues long Guilherme et al. (36, 38)
Structure Alpha helical and beta-sheet conformation, encompasses both
T and B epitopes
Guilherme et al. (37)
Experimental assays Several animal models (BALB/c, C57BL6, Swiss, and HLA class
II transgenic mice)
Guilherme et al. (38), Guerino et al. (39), Postol
et al. (40), De Amicis Marafigo et al. (41)
Immunogenicity and safety
and survival rate
Specific and high titers of opsonic IgG antibodies Guilherme et al. (38), Guerino et al. (39), Postol
et al. (40), De Amicis Marafigo et al. (41)Absence of cross reactivity with human heart-tissue proteins
Long period of survival after S. pyogenes challenge
FIGURE 2 | Schematic representation of heart-tissue infiltration
byT cells and autoimmune reactivity. S. pyogenes-reactive T cells
infiltrate both the myocardium and valvular tissue through specific
integrins (VCAM, ICAM) and chemokines (CCL1/I-309, CXCL3/MIP1α,
CXCL9/Mig) (16, 17). Once in the myocardium, T cells recognized
cardiac myosin. In the valves, vimentin, collagen VI, and other
proteins are the targets of autoimmune reactions. Several
inflammatory cytokines are involved in the inflammatory process. The
presence of large numbers of regulatory cytokines (IL-4 and IL-10) in
the myocardium tissue allowed the cure of myocarditis, while the low
numbers of IL-4 producing cells in the valves contributes to the
permanent valve damage (18).

























































Guilherme and Kalil Rheumatic fever and autoimmune reactions
(PDIA3) protein and a 78-kDa glucose-regulated protein precur-
sor (HSPA5) as targets of the autoimmune reactions (34). It is
interesting to note that apparently the recognition by T cells occurs
in a cascade of reactivity from the myocardium to the valves.
In summary several cardiac proteins and streptococcal M pep-
tides are recognized by both antibodies and T cells. The cross-
reactivity might occur first through mimicry that results in the
recognition of other human proteins, especially valve proteins,
and eventually through epitope spreading and degeneracy mech-
anisms that amplified the number of self antigens that are targets
of the autoimmune reactions.
ANTI-S. PYOGENES VACCINE DEVELOPMENT
The epidemiological growth of streptococcal diseases in undevel-
oped and developing countries has encouraged many groups to
study vaccine candidates for preventing Group A Streptococcus
(GAS) infections.
There are four anti-GAS vaccine candidates that target the M
protein and eight other candidates targeting alternative strepto-
coccal antigens, including group A CHO, C5a peptidase (SCPA),
cysteine protease (Spe B), binding proteins similar to fibronectin,
opacity factor, lipoproteins, Spes (super antigens), and streptococ-
cal pili (35).
We developed a vaccine epitope (StreptInCor) composed of 55
amino acid residues of the C-terminal portion that is highly con-
served among S. pyogenes. The StreptInCor epitope is recognized
by individuals bearing different HLA class II molecules and could
be considered a universal vaccine epitope (36, 37).
Using BALB-c, Swiss, and HLA class II transgenic mice, we eval-
uated the immune response over an extended period and found
that StreptInCor was able to induce a robust immune response in
all models (38–40). Vaccinated Swiss mice challenged with a viru-
lent strain of S. pyogenes had 87% survival over 30 days. No cross-
reaction was observed against cardiac proteins (40). The safety
of the vaccine epitope was evaluated by histopathology and no
autoimmune or pathological reactions were observed in the heart
or other organs (39). Anti-StreptInCor antibodies were able to
neutralize/opsonize S. pyogenes strains, thus indicating that immu-
nization with StreptInCor is effective against several S. pyogenes
strains and can prevent infection and subsequent sequelae without
causing deleterious reactions (41). These properties are summa-
rized in Table 3. Taking all results into consideration, StreptInCor
could be a safe and effective vaccine against streptococcus-induced
disease.
CONCLUSION
The autoimmune process leading to the formation of heart lesions
in RHD involves several genes that control both the innate and
adaptive immune response. Consequently, several molecules play
a role in the different phases of the disease. The molecular mimicry
mechanism leads to the recognition of self proteins, mainly heart-
tissue proteins, in the case of RHD. The autoimmune reactions
are exacerbated by the inflammatory T helper 1 (Th1) and Th17
cytokines. Figure 2 summarizes the events leading to myocardi-
tis and rheumatic valvulitis, and later chronic rheumatic heart
disease.
The knowledge acquired by us and others as mentioned
through the text, allowed the search of a protective epitope giving
a perspective of development of an effective and safe vaccine.
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